Hong Kong Pharma Digital Technology Holdings Limited (HKPD) Cash Flow Statement
Where HKPD’s cash came from and went, FY2026
March 31, 2026 · U.S. dollars- Cash from operations
- −$751,602 −232.0% vs FY2025
- Capital expenditures
- $35,470 0.3% of revenue
- Free cash flow
- −$787,072 −5.9% margin
- Returned to shareholders
- —
- Change in cash
- −$527,280 cash at year-end $221,841
Drawn to scale: where the cash came from and how it was used. Hover for values.
HKPD operating cash flow, capex and free cash flow
HKPD cash flow trends, FY2023–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $1.7MFY2023 | −$751,602FY2026 | — | |
| Capital expenditures | $117,705FY2023 | $35,470FY2026 | −33.0%/yr | |
| Free cash flow | $1.6MFY2023 | −$787,072FY2026 | — | |
| Free cash flow margin | 12.8%FY2023 | −5.9%FY2026 | −18.7 pts | |
| Operating cash flow / net income | 1.73FY2023 | −0.30FY2024 | −2.03 | |
| Capex / revenue | 0.9%FY2023 | 0.3%FY2026 | −0.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
HKPD cash flow by activity
HKPD net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
HKPD cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Operating activities | ||||
| Net income | −$1.1M | −$27,056 | $1.3M | $998,196 |
| Depreciation & amortization | $687,117 | $1.1M | $925,576 | $714,586 |
| Change in working capital | $725,825 | −$520,246 | −$2.6M | $14,297 |
| Other non-cash items | −$1.0M | $43,145 | −$708 | $0 |
| Cash from operating activities | −$751,602 | $569,214 | −$394,330 | $1.7M |
| Investing activities | ||||
| Capital expenditures | −$35,470 | −$154,988 | −$88,018 | −$117,705 |
| Investments (net) | $900,000 | −$2.5M | −$40,796 | −$132,095 |
| Acquisitions & other investing | −$7,073 | $154,988 | $88,018 | $117,705 |
| Cash from investing activities | $857,457 | −$2.5M | −$40,796 | −$132,095 |
| Financing activities | ||||
| Net borrowing (repayment) | −$630,225 | −$927,307 | $373,031 | −$1.2M |
| Shares issued | $0 | $4.3M | $509,501 | $0 |
| Other financing | $0 | −$1.4M | −$345,217 | $0 |
| Cash from financing activities | −$630,225 | $2.0M | $537,315 | −$1.2M |
| Summary | ||||
| Net change in cash | −$527,280 | $121,864 | $102,644 | $439,634 |
| Cash at end of period | $221,841 | $749,121 | $627,257 | $524,613 |
| Free cash flow | −$787,072 | $414,226 | −$482,348 | $1.6M |
| Free cash flow margin | −5.9% | 2.0% | −2.9% | 12.8% |
| Capex / revenue | 0.3% | 0.8% | 0.5% | 0.9% |
| Operating cash flow / net income | — | — | −0.30 | 1.73 |
| Jun '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$1.3M | $153,735 | −$427,808 | −$855,616 | −$427,808 | $828,560 | $414,280 | $1.1M | $540,340 | $249,036 |
| Depreciation & amortization | $227,453 | $47,392 | $315,717 | $631,433 | $315,717 | $441,938 | $220,969 | $477,868 | $238,934 | $447,706 |
| Change in working capital | $1.4M | −$823,824 | $81,534 | $163,068 | $81,534 | −$897,748 | −$448,874 | −$1.6M | −$796,525 | −$1.1M |
| Other non-cash items | −$823,883 | $378,680 | −$61,396 | −$122,791 | −$61,396 | $380,370 | $190,185 | −$275,910 | −$137,955 | $288,436 |
| Cash from operating activities | −$507,584 | −$244,017 | −$91,953 | −$183,906 | −$91,953 | $753,120 | $376,560 | −$310,412 | −$155,206 | −$83,918 |
| Investing activities | ||||||||||
| Capital expenditures | −$37 | −$35,433 | −$14,440 | −$28,880 | −$14,440 | −$41,036 | −$20,518 | −$1,006 | −$503 | −$51,730 |
| Acquisitions & other investing | $899,993 | −$7,066 | −$1.2M | −$2.3M | −$1.2M | −$65,308 | −$32,654 | $210,864 | $105,432 | −$198,924 |
| Cash from investing activities | $899,956 | −$42,499 | −$1.2M | −$2.3M | −$1.2M | −$106,344 | −$53,172 | $209,858 | $104,929 | −$250,654 |
| Financing activities | ||||||||||
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$360,671 | −$269,554 | $1.5M | $2.9M | $1.5M | −$912,024 | −$456,012 | $475,774 | $237,887 | $61,542 |
| Cash from financing activities | −$360,671 | −$269,554 | $1.5M | $2.9M | $1.5M | −$912,024 | −$456,012 | $475,774 | $237,887 | $61,542 |
| Summary | ||||||||||
| Net change in cash | −$191,371 | −$557,750 | — | — | — | — | — | — | −$252,776 | $252,776 |
| Cash at end of period | — | $191,371 | $749,121 | — | — | — | — | $252,776 | — | $252,776 |
| Free cash flow | −$507,621 | −$279,450 | −$106,392 | −$212,784 | −$106,392 | $712,084 | $356,042 | −$311,418 | −$155,709 | −$135,648 |
| Free cash flow margin | −8.1% | −3.9% | −2.3% | −2.3% | −2.3% | 6.4% | 6.4% | −3.2% | −3.2% | −1.9% |
| Capex / revenue | 0.0% | 0.5% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% | 0.0% | 0.0% | 0.7% |
| Operating cash flow / net income | — | −1.59 | — | — | — | 0.91 | 0.91 | −0.29 | −0.29 | −0.34 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
HKPD cash generation
In fiscal 2026 (ended March 31, 2026), Hong Kong Pharma Digital Technology generated -$0.8 million of cash from operations (down 232.0%) and spent $0.0 million on capital expenditures, leaving free cash flow of -$0.8 million, −5.9% of revenue. Cash and equivalents fell by $0.5 million over the year.
Related: HKPD income statement, HKPD balance sheet. See the HKPD stock overview for the latest quote and news.
HKPD cash flow FAQ
What is Hong Kong Pharma Digital Technology's free cash flow?
Hong Kong Pharma Digital Technology's free cash flow was -$0.8 million in fiscal 2026: -$0.8 million of operating cash flow minus $0.0 million of capital expenditures It was $0.4 million a year earlier..
How much cash does Hong Kong Pharma Digital Technology generate from operations?
Hong Kong Pharma Digital Technology generated -$0.8 million of cash from operating activities in fiscal 2026.
How much does Hong Kong Pharma Digital Technology spend on capital expenditures?
Hong Kong Pharma Digital Technology spent $0.0 million on capital expenditures in fiscal 2026, 0.3% of revenue, compared with $0.2 million the year before.